论文部分内容阅读
目的:确定晚期浆液性卵巢上皮癌存活与WT1基因表达的相关性。方法:收集2002～2010年经过完整术后化疗的晚期浆液性卵巢上皮癌女性患者168例,最终纳入研究109例。收集入选病例的完整病历资料及石蜡包埋的组织块切片后,WT1免疫染色并据此分组,采用卡普兰-迈耶曲线及COX回归法进行生存分析。结果:55例患者的病理组织WT1染色呈阳性,54例阴性。WT1阳性组的卵巢癌病灶大小和淋巴转移率显著高于WT1阴性组(P<0.05)。WT1阴性患者5年生存率为39.4%,WTI阳性患者5年生存率为10.7%,二者差异有统计学意义(P<0.05)。结论:WT1基因表达与晚期浆液性卵巢上皮癌预后不良密切相关。
Objective: To determine the relationship between the survival of advanced serous ovarian cancer and the expression of WT1 gene. Methods: A total of 168 women with advanced serous epithelial ovarian cancer who underwent complete postoperative chemotherapy from 2002 to 2010 were enrolled. Finally, 109 women were included in the study. After collecting the complete medical records and paraffin-embedded sections of the selected cases, WT1 was immunostained and grouped accordingly. The Kaplan-Meier curves and COX regression were used for survival analysis. Results: 55 cases of pathological tissue WT1 staining was positive, 54 cases were negative. The size and lymph node metastasis of ovarian cancer in WT1-positive group were significantly higher than those in WT1-negative group (P <0.05). The 5-year survival rate was 39.4% in WT1-negative patients and 10.7% in WTI-positive patients, the difference was statistically significant (P <0.05). Conclusion: The expression of WT1 is closely related to the poor prognosis of advanced serous ovarian cancer.